Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accelerated Approval Could Spur Development Of Patient-Reported Outcomes Tools

Executive Summary

A subtle takeaway from the Oncologic Drugs Advisory Committee’s March 20 review of GlaxoSmithKline’s Votrient (pazopanib) for treatment of advanced soft tissue sarcoma was that accelerated approval, with a post-marketing requirement to confirm clinical benefit in a difficult-to-treat population, could incentivize sponsors to develop instruments for assessing symptom improvement.

You may also be interested in...



Linking E-Health Records With Claims Offers Context On Outcomes – Optum Labs Exec

Despite the promise electronic health records hold for comparative effectiveness research, clinical information needs to be lined up with claims data to get a more complete picture, Optum Labs’ William Crown said during the recent Comparative Effectiveness Summit.

Oncology Experience With PROs

There has been some success in getting PRO data into oncology labeling, but also notable failures.

Can Social Media Help Validate Patient-Reported Outcomes? FDA Reviewer Gives “Resounding Yes”

Work needs to be done to allow for the use of social media to support content validity of patient-reported outcomes, but one FDA endpoints reviewer says there is a place for social media to work alongside traditional methods of validating PROs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel